Dechra Pharmaceuticals — Investor Presentation (November 2020)
20 slides from Dechra Pharmaceuticals's investor presentation, November 2020
Slide 1: Introduction to Dechra: Improving Global Animal Health and Welfare
Introduction to Dechra Improving Global Animal Health and Welfare
Slide 2: Dechra is a global specialist veterinary pharmaceuticals business
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality productsexclusively for veterinarians worldwide. For more information please visit www.dechra.com Companion Animal Products (C
Slide 3: Contents
Contents • The Veterinary Market • Our History • Strategy and Progress • Financial Track Record 2
Slide 4: The Animal Health Market
The Animal Health Market The Animal Health Market by Species Market Share by Competitor 2019 Zoetis: 13.40% Boehringer Ingelheim: 9.50% Merck/MSD Animal Health: 9.30% Elanco: 6.60% IDEXX Laboratories: 4.90% Bayer Animal Health: 3.80% Ceva Sante Animal: 2.80% Virbac: 2.30% Philbro Animal Health: 1.70
Slide 5: Sustainable Global Market Dynamics
Sustainable Global Market Dynamics Companion Animal Products Food producing Animal Products (CAP) (FAP) • Pet ownership increasing in developing • Increased world demand for high quality animal countries protein and dairy products • Pet spending growing (7 billion people consume animal protein) • In
Slide 6: Our History
Our History Commenced 2014 trading in Italy Acquired PSPC US bolt-on 2018 Acquired Le Vet Adds to EU Acquired Venco Access to Acquired AST Farma Strengthens Dutch product portfolio Brazil and South market position and American markets provides direct-to- vet relationship ab c ab c 2015 Commenced tra
Slide 7: FY20 Sales Profile
FY20 Sales Profile Revenue by Product Category Sales by Region (at AER) CAP Equine FAP Nutrition Other Europe USA RoW 6
Slide 8: Our Strategy
Our Strategy To continue to develop our position as a global, high margin, cash generative, veterinary pharmaceuticals and related products business by: a b c Portfolio Focus Maximising revenue from our existing portfolio Pipeline Delivery Innovation, development and registration of new products Geo
Slide 9: Portfolio Focus
Portfolio Focus Current portfolio continues to grow Clear focus on therapeutic sectors Market leading position in endocrinology, dermatology and pain management Education provides new market opportunities Key brands’ market penetration not yet maximised Ability to leverage the strong Dec
Slide 10: Pipeline Delivery
Pipeline Delivery Proven long term track record of delivery Recent approvals received on major novel, generic and vaccine products Currently 37 projects in the product development pipeline Registration activity on existing products into new markets New opportunities being explored Licenc
Slide 11: Geographical Expansion
Geographical Expansion Increasing area of focus Sales through own subsidiaries and marketing partners Own branded sales and marketing expansion continues organically: Canada, Poland, Austria, and through acquisition: Brazil, Australia and New Zealand All recently entered countries delivering
Slide 12: Acquisition
Acquisition Nice to have, not need to have Increase footprint, create synergies or add new technical or product capabilities (or any combination) 19 acquisitions in 20 years all integrated to expectations 6 acquisitions in past 24 months all on track 48% share in Medical Ethics Pty Ltd A
Slide 13: FY20 Acquisition
FY20 Acquisition Busy year for M&A and Dechra has continued to deliver against its acquisition strategy During the 2020 financial year, the Company completed: Mirataz® (£34.9 million) Medical Ethics (increased investment of £7.6 million) Ampharmco (£24.3 million) Completed Osurnia® in Ju
Slide 14: Covid-19
Covid-19 Operations continued throughout a difficult year • Successfully remained operational across the business throughout the epidemic • No employees furloughed in any country: • Job security • Enhanced loyalty • Innovative ways of working • Sad loss of Group Manufacturing & Supply Chain Director
Slide 15: ESG Strategy
ESG Strategy Committed to sustainable development • Our Purpose is the sustainable improvement of global animal health and welfare • We have chosen to link our strategy to the United Nations Sustainable Development Goals (SDG’s) • This provides a framework for activities we were already doing • We i
Slide 16: Summary
Summary 22 consecutive years of strong growth Highly cash generative Proven delivery of strategy Excellent, experienced management team Sustainable market dynamics Good future growth prospects 15
Slide 17: Appendices
Dechra Pharmaceuticals PLC Appendices
Slide 18: Glossary
Glossary AER: Actual Exchange Rate CAP: Companion Animal Products CER: Constant Exchange Rate EPS: Earnings Per Share ERP: Enterprise Resource Planning EU: Europe FAP: Food producing Animal Products FX: Foreign Exchange IFRS: International Financial Reporting Standards NA: North America NCI: Non Con
Slide 19: Forward-looking statements and trademarks
This document contains certain forward-looking statements which reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in th
Slide 20: Dechra Pharmaceuticals PLC contact details
® Dechra Pharmaceuticals PLC 24 Cheshire Avenue Cheshire Business Park Lostock Gralam Northwich CW97UA T: +44 (0) 1606 814730 F: +44 (0) 1606 814731 E: corporate.enquiries@dechra.com www.dechra.com Stock code: DPH ®
Dechra Pharmaceuticals — Investor Presentation (November 2020) on 6ix